SynBioVen
VC Fund
London, United Kingdom
SynBioVen is a VC fund in London focused on Biotechnology and AgTech. SynBioVen is focused on supporting the next generation of synthetic biology scientists, founders and start-ups.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 54%
Last updated:
For AI agents: llms.txt
Industries SynBioVen invests in
Stages SynBioVen invests in
Countries SynBioVen invests in
Round sizes
Round size
- Seed
- $1.2M–$6.7M
- Pre-Seed
- $1M–$1M
- Series A
- $9.5M–$10M
Investment Focus
Industry
- Biotechnology 6 (46%)
- AgTech 2 (15%)
- Machine Learning 2 (15%)
- Medical 1 (8%)
- Textiles 1 (8%)
Stage
- Seed 6 (46%)
- Series A 2 (15%)
- Pre-Seed 1 (8%)
Country
- United Kingdom 4 (31%)
- France 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry. | $10.3M / Series A / Feb 17, 2026 | ||
| Scindo is a cleantech start-up harnessing the power of enzymes to recycle the unrecyclables. We are targeting plastics that cannot be efficiently recycled with current methodologies, to turn them into high-value molecules that can be used in a plethora of industries. We are creating a more circular economy for plastics by developing an alternativeto landfills and incineration. | $5.4M / Seed / Sep 23, 2025 | ||
Solena Materials
|
Solena is a protein material design company. It use world-leading computational design, machine learning, and automation to accelerate the development of bespoke materials targeted at multiple sectors, from fashion apparel to medical textiles. The new protein-based fibers will replace materials extracted from nature such as silk andpetrochemically-derived materials, to create a new world of biodegradable, functional, and sustainable smart materials for consumers, industry, and the planet. | $6.7M / Seed / May 05, 2025 | |
| Generare is a biotech startup that discovers next-generation medicines and high-value molecules hiding in soil bacteria. | $5.5M / Seed / Oct 07, 2024 | ||
| CHAIN Biotechnology is a microbiome therapeutics company with a novel drug development platform targeting chronic gut-related diseases. CHAIN is developing several therapeutic compounds targeted to the gut microbiome in the large intestine that can be delivered by our CADD technology. | $2.3M / Seed / Jul 26, 2023 | ||
| Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry. | $2M / Seed / May 16, 2023 | ||
| Multus Biotechnology is a global leader in cell culture media design, helping biomanufacturing companies shorten their time to market while improving supply chain security. By combining high-throughput robotic automation and ML, Multus revolutionizes cell culture media development - delivering breakthrough performance and efficiency that werepreviously unattainable.Multus’ experienced, multi-disciplinary team of scientists and engineers is redefining the future of biomanufacturing. Harnessing the power of biology, automation, and machine learning, we accelerate the creation of high-performance, resource-efficient cell culture media, empowering the global bioeconomy and enabling the next generation of essential therapies, food, and materials. | $9.5M / Series A / Jan 16, 2023 | ||
| Harnessing nature's potential | $1.2M / Seed / Nov 14, 2022 | ||
| Scindo is a cleantech start-up harnessing the power of enzymes to recycle the unrecyclables. We are targeting plastics that cannot be efficiently recycled with current methodologies, to turn them into high-value molecules that can be used in a plethora of industries. We are creating a more circular economy for plastics by developing an alternativeto landfills and incineration. | Seed / Apr 28, 2022 | ||
| Scindo is a cleantech start-up harnessing the power of enzymes to recycle the unrecyclables. We are targeting plastics that cannot be efficiently recycled with current methodologies, to turn them into high-value molecules that can be used in a plethora of industries. We are creating a more circular economy for plastics by developing an alternativeto landfills and incineration. | $1M / Pre-Seed / Apr 28, 2022 | ||
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does SynBioVen invest in?
SynBioVen invests primarily in Biotechnology, AgTech and Machine Learning startups, most often at Seed and Series A stage. Most of the 13 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does SynBioVen invest in?
SynBioVen typically joins rounds of $1.2M–$6.7M at Seed, $1M–$1M at Pre-Seed and $9.5M–$10M at Series A. These are whole funding-round sizes, not SynBioVen's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds SynBioVen took part in.
When did SynBioVen last invest?
The most recent investment recorded for SynBioVen closed in Feb 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
